Skye Bioscience Q2 2026 operating loss narrows 39.37% to $11.06 million
SKYE•Strategic update
Skye terminated the CBeyond program, paused nimacimab work, and signed a deal to acquire Redx and rebrand as Fibrx Therapeutics.
Q2 operating loss and net loss narrow
Skye Bioscience posted a Q2 operating loss of $11.06 million, narrowing from $18.24 million a year earlier.
Net loss improved to $10.79 million from $17.62 million in the prior-year quarter.
R&D spending falls sharply after program changes
Research and development expense plunged 73% to $3.94 million due to terminating CBeyond clinical activities and pausing nimacimab R&D.
General and administrative costs edged down 1% to $3.87 million on lower headcount, partly offset by higher legal fees.
